Skip to main content

Thromboelastography during treatment with activated protein C


Activated protein C (rhAPC) infusion increases fibrinolysis, which is very difficult to evaluate with standard tests. We used TEG to monitor the coagulation in our patients during the infusion of rhAPC.

Materials and methods

Six patients with severe sepsis were treated with rhAPC (24 μg/kg/hour for 96 hours). TEG (ETEG 3000; Hemoscope Corp., Skokie IL, USA) was carried out on native blood before (T0), at 24 hours (T1), 48 hours (T2), 72 hours (T3), 96 hours (T4) during and 24 hours after the end (T5) of rhAPC treatment. Analysis of differences between data was carried out with the Student t test for paired data (differences statistically significant for P < 0.05).


Data are expressed as the mean and standard deviation. Results obtained are shown in Table 1 and Figs 1 and 2. * indicates the statistically significant results.

Table 1 (abstract P346)
Figure 1

(abstract P346)

Figure 2

(abstract P346)


TEG is a reliable tool for monitoring fibrinolysis during rhAPC. Fibrinolyisis is more evident during the first 48 hours of infusion, probably because of a new equilibrium in the coagulation system reached after that period.

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Panascia, E., Castiglione, G., Calabrese, P. et al. Thromboelastography during treatment with activated protein C. Crit Care 9, P346 (2005).

Download citation


  • Public Health
  • Standard Deviation
  • Emergency Medicine
  • Severe Sepsis
  • Standard Test